This text is a result of machine translation.
The official results of the French parliamentary elections were announced, and the ruling party coalition held a relatively large number of seats
Cbcirc: focus on investigating and dealing with the illegal transfer of interests through credit, bonds, discount and other means
Big Pharma CCHT’s Domination Unlikely to Fade Soon Despite Official Bulk Buying
The producer of long-acting growth hormone acupunctures, vaccines and other drugs, looks set to offset the effects of so-called “centralized procurement” on its product prices with more aggressive expansion into private hospitals. So far, its monopoly appears unshakable, but with more competitors upping the stakes, how long will it last?
Feb 21, 2022 02:30 PM
Shenzhen textile A: the order of line 7 is full, and the production line speed is climbing
Taier shares: the contract dispute case against Cao Linbin was accepted by the court
2022 China AI Health 30 Report
Yunnan Baiyao: its two subsidiaries, Wenshan and Dali, hold the drug registration certificate of qianjintengsu tablets
*Huaxun stock may be suspended
Beautiful Ecology: the net profit in the first quarter increased by 24.92% to 1.9755 million yuan
Families of non registered residence residents in Nanjing can apply for house purchase after accumulatively paying social security for 6 months within one year
Yunnan Baiyao's Revenue Rises 33%; Net Profit Falls 40% in 1Q 2021
On April 27, Yunnan Baiyao released a report for the first quarter of 2021 showing that the company's total operating revenue for the first quarter was 10.33 billion yuan, up 33.4% year-on-year; its operating profit was 880 million yuan, down 41.8% year-on-year; its net profit attributable to shareholders of the listed company was 760 million yuan.
Apr 30, 2021 02:07 AM
Yingkang life: it is expected to lose 300 million yuan to 370 million yuan in 2021
Nissan announced the progress of assisted driving technology, which can detect the deceleration traffic flow
Hydrogen fuel cell concept stocks strengthened, and Beijing shares and Zhenyang development limited
Jiangsu Hengrui, Chinese Cancer Drugmaker Emerging from the Shadows
A flagship in the Chinese oncology market, Jiangsu Hengrui Medicine (600276:SH) was accused of corruption in sales. This was soon followed by good news – an approval of a Phase III clinical test. Will a bright future erase the black stain?
May 22, 2020 10:52 PM
Digital Zhengtong: new orders signed in the first two months increased by more than 60% year-on-year
Half day main capital net inflow of power equipment, non bank finance, selling banks, etc
Yichang Technology: the net profit in 2021 was 74.3696 million yuan, with a year-on-year increase of 12.95%
Galaxy Securities: the penetration rate of assisted reproduction in China is expected to increase in the future
Interview With TI5 ROBOT: The Rise of the Robot Industry
May 18, 2023 10:38 AM
TOPS in Shanghai: The New Trends in the Pet Industry's Overseas Expansion
May 12, 2023 01:33 PM